ProCE Banner Activity

Rapid-fire Answers to Key Questions in Treating Myelofibrosis

Clinical Thought

In this commentary, 3 experts discuss key topics from a live meeting on contemporary management of patients with myelofibrosis, including approaches to patients with low platelets, defining JAK inhibitor failure, and emerging therapeutic strategies.

Released: July 24, 2023

Share

Faculty

John Mascarenhas

John Mascarenhas, MD

Director
Center of Excellence in Blood Cancers and Myeloid Disorders
Director
Adult Leukemia Program
Leader
Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Ruben A. Mesa

Ruben A. Mesa, MD

President
Enterprise Cancer Service Line
Executive Director
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Enterprise Senior Vice President
Atrium Health
Vice Dean for Cancer Programs
Wake Forest University School of Medicine
Professor of Medicine
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Brady L. Stein

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Inc., CTI BioPharma, GSK, and Incyte Corporation.

AbbVie, Inc.

CTI BioPharma

GSK

Incyte Corporation

Faculty Disclosure

Primary Author

John Mascarenhas, MD

Director
Center of Excellence in Blood Cancers and Myeloid Disorders
Director
Adult Leukemia Program
Leader
Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

John Mascarenhas, MD: consultant/advisor/speaker: AbbVie, Bristol-Myers Squibb, Celgene, CTI Bio, Geron, GlaxoSmithKline, Imago, Incyte, Kartos, Kayropharm, MorphoSys, Novartis, Pfizer, PharmaEssentia, Sierra; researcher: AbbVie, Bristol-Myers Squibb, Celgene, CTI Bio, Geron, Incyte, Novartis.

Ruben A. Mesa, MD

President
Enterprise Cancer Service Line
Executive Director
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Enterprise Senior Vice President
Atrium Health
Vice Dean for Cancer Programs
Wake Forest University School of Medicine
Professor of Medicine
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Ruben A. Mesa, MD, FACP: consultant/advisor/speaker: AbbVie, Blueprint, Bristol-Myers Squibb, CTI, Incyte, Sierra, Telios; researcher: Blueprint, CTI, GlaxoSmithKline, Imago, Incyte, Ionis, Morphosys, Pharmessentia.

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Brady L. Stein, MD, MHS, has no relevant financial relationships to disclose.